AU Patent

AU2019277362A1 — Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome

Assigned to Mayne Pharma International Pty Ltd · Expires 2021-01-21 · 5y expired

What this patent protects

The present invention concerns methods for treating high-risk basal cell carcinoma (BCC) or high-risk basal cell carcinoma nevus syndrome (BCCNS) in a subject, comprising administering a composition comprising an azole inhibitor of the Hedgehog signaling pathway (azole inhibitor)…

USPTO Abstract

The present invention concerns methods for treating high-risk basal cell carcinoma (BCC) or high-risk basal cell carcinoma nevus syndrome (BCCNS) in a subject, comprising administering a composition comprising an azole inhibitor of the Hedgehog signaling pathway (azole inhibitor) to the subject.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019277362A1
Jurisdiction
AU
Classification
—
Expires
2021-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Mayne Pharma International Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.